Ubrigene's last reported valuation, Dec 2020. Nothing priced has surfaced since.
- ·The complete investor list: 18 names
- ·Watch Ubrigene: the Monday email on marks, rounds and moves
Valuation timeline
0 priced rounds · 33 daily marks since · Sep 2026 – Oct 2026Membership and data by Private Market View
Ubrigene funding history
No funding rounds for Ubrigene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Ubrigene valuation
Ubrigene's last reported valuation was $50.8 million in Dec 2020. No priced round, secondary trade or fund mark has surfaced since.
How Ubrigene's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Ubrigene, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by last reported valuation. Question about this number? Full methodology →
Frequently asked about Ubrigene
- What is Ubrigene worth?
- Ubrigene is valued at $50.8M as of Oct 2026. Ubrigene's last reported valuation, Dec 2020. Nothing priced has surfaced since.
- How much has Ubrigene raised?
- Ubrigene has raised $142.9M in total funding across its recorded rounds.